Drug intelligence / Profile preview

astilbin

Development stage
Preclinical
Modality
Small Molecules
Administration
Oral, Topical, Intravenous
01

Overview

Astilbin is a naturally occurring flavanonol glycoside (a type of flavonoid) found in various plants such as St. John’s wort (Hypericum perforatum), Smilax glabra rhizomes, and Astilbe species. It is used in traditional Chinese medicine and has demonstrated a range of pharmacological activities including anti-inflammatory, immunosuppressive, antioxidant, antibacterial, hepatoprotective effects and potential anticancer properties. Mechanistically, astilbin modulates immune responses by suppressing effector CD4+ T cell function and inflammatory cytokine production (such as TNF-α and IL-6), inhibits NF-κB signaling pathways involved in inflammation and cancer progression, reduces oxidative stress via Nrf2 activation pathways, inhibits enzymes like angiotensin-converting enzyme and aldose reductase relevant to metabolic diseases such as diabetes complications. Preclinical studies suggest efficacy for conditions including arthritis (with less toxicity than cyclosporine A), psoriasis-like skin disease via ferroptosis/cGAS-STING pathway modulation[7], diabetic nephropathy through TGF-β/Smad inhibition[10], burn wound healing[1], radioprotection[9], neurodegenerative diseases[4], gastric cancer apoptosis induction[3] among others.

Other names
Taxifolin 3-O-rhamnosideTaxifolin3-O-rhamnosideTaxifolin-3-O-rhamnosideDihydroquercitrin(2R-cis)-isomer of astilbin(2S-cis)-isomer of astilbinisoastilbinneoisoastilbin
02

Targets

CYP2D6 (Cytochrome P450 2D6)KLF4 (Krüppel-like factor 4)CYP1B1 (Cytochrome P450 1B1)

Beyond the preview

Go deeper on astilbin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on astilbin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call